Balchem Corporation (BCPC) Stock Price & How to Invest

Balchem Corporation is a specialty ingredients company organized into three segments: Human Nutrition and Health (choline nutrients, encapsulated ingredients, flavor and food systems), Animal Nutrition and Health (microencapsulated feed additives, chelated minerals, and choline chloride for livestock and pets), and Specialty Products (ethylene-oxide sterilization for medical devices, plus fumigants for food safety). It is a leader in choline chemistry and microencapsulation, selling into food, beverage, dietary supplement, animal feed, and healthcare end markets that tend to hold up through economic cycles.

The investment picture is one of a steady compounder rather than a fast grower. Balchem has strung together many consecutive quarters of year-over-year adjusted EBITDA growth, generates strong free cash flow, and reinvests through bolt-on acquisitions and capacity expansion. The trade-off is valuation: the stock carries a premium earnings multiple that already prices in continued execution, so returns depend on the company sustaining mid-single-digit organic growth and margin discipline while navigating input-cost swings and regulatory scrutiny of ethylene oxide and choline chloride.

The 2026 results have kept that record intact and added some acceleration. Second-quarter net sales (quarter ended June 30, 2026) reached a record of about $284 million, up about 11% year over year, net income was about $44.6 million, and adjusted EPS of $1.49 beat the $1.42 consensus; management described it as the 28th consecutive quarter of year-over-year adjusted EBITDA growth. Trailing twelve-month revenue is about $1.09 billion with net income near $164 million. The stock is up about 17% over one year, giving a market value near $5.4 billion. Third-quarter results are scheduled for October 23, 2026, with consensus near $1.53 per share on revenue of about $289 million.

Balchem trades at a premium earnings multiple (about 34x trailing and 27x forward as of October 2026), so any slowdown in growth or margin pressure could compress the valuation meaningfully. Ethylene-oxide operations face ongoing environmental and regulatory scrutiny and potential litigation risk given health concerns around the compound. Choline chloride pricing and trade dynamics, including a European Commission investigation into tariffs, can pressure the Animal Nutrition segment. Input-cost inflation, foreign-exchange swings, and customer concentration in some categories add variability. As a mid-cap it is more sensitive to single-segment weakness than a diversified large cap.

4 analysts publish price targets on BCPC, averaging $209.25 against a $170.73 price as of October 2026, or +22.6%. The published targets run from $165.00 to $242.00, a moderate spread, and the ratings split 2 buy, 1 hold, 0 sell. Over the last six months there have been 2 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full BCPC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Balchem Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Human Nutrition and Health momentum. The largest segment benefits from durable demand for choline, minerals, and specialty food and supplement ingredients tied to health and wellness trends. The most optimistic published target, $242.00, assumes this works close to its best case.

The case against. Balchem trades at a premium earnings multiple (about 34x trailing and 27x forward as of October 2026), so any slowdown in growth or margin pressure could compress the valuation meaningfully. The most pessimistic target, $165.00, is roughly what BCPC is worth if this bites instead.

Read the full bull and bear case on BCPC, including what would have to change to break either one. Walnut is not an investment adviser.

No. Balchem Corporation (BCPC) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Balchem Corporation's investor relations page or your broker.

• Revenue (TTM): ~$1.09B (Q2 2026 up ~11% YoY)
• Net income (TTM): ~$164M (net margin ~15%)
• Q2 2026 net sales: ~$284M (record)
• Q2 2026 adjusted EPS: ~$1.49 vs ~$1.42 estimate
• Operating margin: ~21% (gross ~36%)
• P/E (trailing / forward): ~34x / ~27x
• Market cap: ~$5.4B (October 16, 2026)
• Dividend: ~$0.96 annual (~0.6% yield)

Balchem posted record second-quarter 2026 net sales of about $284 million, up roughly 11% year over year, and adjusted EPS of $1.49 ahead of estimates, extending its streak of year-over-year adjusted EBITDA growth to 28 quarters. At $170.80 the stock trades at about 34x trailing and 27x forward earnings and about 20x EV/EBITDA, a multiple that prices in continued consistency. Q3 results arrive October 23, 2026, with consensus near $1.53 per share.

Other names that sit close to BCPC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get BCPC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so BCPC sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where BCPC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

BCPC is a durable, cash-generative niche ingredients business priced for its consistency, so the debate is about valuation rather than business quality.

Whether BCPC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BCPC a buy or a sell?, and where the stock could go from here in the BCPC stock forecast.

For income investors, whether BCPC pays a dividend and how the payout looks is covered in does BCPC pay a dividend? And to weigh BCPC against a peer, read the full side-by-side comparisons: BCPC vs BASFY and BCPC vs EMN.